Genomic and transcriptomic analyses of tumor tissue from a patient with acquired resistance to sacituzumab govitecan revealed a parallel genomic alteration in TACSTD1/TROP2 and TOP1, which encode TROP2 protein and the SN-38 drug target topoisomerase 1, respectively [52]. Here, TACSTD2 is linked to neoplasm.